178 related articles for article (PubMed ID: 37421953)
1. Machine learning for cryosection pathology predicts the 2021 WHO classification of glioma.
Nasrallah MP; Zhao J; Tsai CC; Meredith D; Marostica E; Ligon KL; Golden JA; Yu KH
Med; 2023 Aug; 4(8):526-540.e4. PubMed ID: 37421953
[TBL] [Abstract][Full Text] [Related]
2. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
3. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
Chen SC; Lo CM; Wang SH; Su EC
BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
5. The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.
Rogers TW; Toor G; Drummond K; Love C; Field K; Asher R; Tsui A; Buckland M; Gonzales M
J Neurooncol; 2018 Mar; 137(1):181-189. PubMed ID: 29218432
[TBL] [Abstract][Full Text] [Related]
6. Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?
Weller M; Reifenberger G
Curr Opin Neurol; 2020 Dec; 33(6):701-706. PubMed ID: 33177376
[TBL] [Abstract][Full Text] [Related]
7. Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results.
Ballester LY; Huse JT; Tang G; Fuller GN
Hum Pathol; 2017 Nov; 69():15-22. PubMed ID: 28549927
[TBL] [Abstract][Full Text] [Related]
8. [Precision Medicine for IDH-mutant Diffuse Glioma(Lower-grade Glioma)].
Mukasa A
No Shinkei Geka; 2022 Jan; 50(1):8-18. PubMed ID: 35169082
[TBL] [Abstract][Full Text] [Related]
9. High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis.
Zheng L; Zhang M; Hou J; Gong J; Nie L; Chen X; Zhou Q; Chen N
Neuropathology; 2020 Dec; 40(6):599-605. PubMed ID: 32761642
[TBL] [Abstract][Full Text] [Related]
10. World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review.
Berger TR; Wen PY; Lang-Orsini M; Chukwueke UN
JAMA Oncol; 2022 Oct; 8(10):1493-1501. PubMed ID: 36006639
[TBL] [Abstract][Full Text] [Related]
11. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N
J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469
[TBL] [Abstract][Full Text] [Related]
12. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Malzkorn B; Reifenberger G
Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
; Brat DJ; Verhaak RG; Aldape KD; Yung WK; Salama SR; Cooper LA; Rheinbay E; Miller CR; Vitucci M; Morozova O; Robertson AG; Noushmehr H; Laird PW; Cherniack AD; Akbani R; Huse JT; Ciriello G; Poisson LM; Barnholtz-Sloan JS; Berger MS; Brennan C; Colen RR; Colman H; Flanders AE; Giannini C; Grifford M; Iavarone A; Jain R; Joseph I; Kim J; Kasaian K; Mikkelsen T; Murray BA; O'Neill BP; Pachter L; Parsons DW; Sougnez C; Sulman EP; Vandenberg SR; Van Meir EG; von Deimling A; Zhang H; Crain D; Lau K; Mallery D; Morris S; Paulauskis J; Penny R; Shelton T; Sherman M; Yena P; Black A; Bowen J; Dicostanzo K; Gastier-Foster J; Leraas KM; Lichtenberg TM; Pierson CR; Ramirez NC; Taylor C; Weaver S; Wise L; Zmuda E; Davidsen T; Demchok JA; Eley G; Ferguson ML; Hutter CM; Mills Shaw KR; Ozenberger BA; Sheth M; Sofia HJ; Tarnuzzer R; Wang Z; Yang L; Zenklusen JC; Ayala B; Baboud J; Chudamani S; Jensen MA; Liu J; Pihl T; Raman R; Wan Y; Wu Y; Ally A; Auman JT; Balasundaram M; Balu S; Baylin SB; Beroukhim R; Bootwalla MS; Bowlby R; Bristow CA; Brooks D; Butterfield Y; Carlsen R; Carter S; Chin L; Chu A; Chuah E; Cibulskis K; Clarke A; Coetzee SG; Dhalla N; Fennell T; Fisher S; Gabriel S; Getz G; Gibbs R; Guin R; Hadjipanayis A; Hayes DN; Hinoue T; Hoadley K; Holt RA; Hoyle AP; Jefferys SR; Jones S; Jones CD; Kucherlapati R; Lai PH; Lander E; Lee S; Lichtenstein L; Ma Y; Maglinte DT; Mahadeshwar HS; Marra MA; Mayo M; Meng S; Meyerson ML; Mieczkowski PA; Moore RA; Mose LE; Mungall AJ; Pantazi A; Parfenov M; Park PJ; Parker JS; Perou CM; Protopopov A; Ren X; Roach J; Sabedot TS; Schein J; Schumacher SE; Seidman JG; Seth S; Shen H; Simons JV; Sipahimalani P; Soloway MG; Song X; Sun H; Tabak B; Tam A; Tan D; Tang J; Thiessen N; Triche T; Van Den Berg DJ; Veluvolu U; Waring S; Weisenberger DJ; Wilkerson MD; Wong T; Wu J; Xi L; Xu AW; Yang L; Zack TI; Zhang J; Aksoy BA; Arachchi H; Benz C; Bernard B; Carlin D; Cho J; DiCara D; Frazer S; Fuller GN; Gao J; Gehlenborg N; Haussler D; Heiman DI; Iype L; Jacobsen A; Ju Z; Katzman S; Kim H; Knijnenburg T; Kreisberg RB; Lawrence MS; Lee W; Leinonen K; Lin P; Ling S; Liu W; Liu Y; Liu Y; Lu Y; Mills G; Ng S; Noble MS; Paull E; Rao A; Reynolds S; Saksena G; Sanborn Z; Sander C; Schultz N; Senbabaoglu Y; Shen R; Shmulevich I; Sinha R; Stuart J; Sumer SO; Sun Y; Tasman N; Taylor BS; Voet D; Weinhold N; Weinstein JN; Yang D; Yoshihara K; Zheng S; Zhang W; Zou L; Abel T; Sadeghi S; Cohen ML; Eschbacher J; Hattab EM; Raghunathan A; Schniederjan MJ; Aziz D; Barnett G; Barrett W; Bigner DD; Boice L; Brewer C; Calatozzolo C; Campos B; Carlotti CG; Chan TA; Cuppini L; Curley E; Cuzzubbo S; Devine K; DiMeco F; Duell R; Elder JB; Fehrenbach A; Finocchiaro G; Friedman W; Fulop J; Gardner J; Hermes B; Herold-Mende C; Jungk C; Kendler A; Lehman NL; Lipp E; Liu O; Mandt R; McGraw M; Mclendon R; McPherson C; Neder L; Nguyen P; Noss A; Nunziata R; Ostrom QT; Palmer C; Perin A; Pollo B; Potapov A; Potapova O; Rathmell WK; Rotin D; Scarpace L; Schilero C; Senecal K; Shimmel K; Shurkhay V; Sifri S; Singh R; Sloan AE; Smolenski K; Staugaitis SM; Steele R; Thorne L; Tirapelli DP; Unterberg A; Vallurupalli M; Wang Y; Warnick R; Williams F; Wolinsky Y; Bell S; Rosenberg M; Stewart C; Huang F; Grimsby JL; Radenbaugh AJ; Zhang J
N Engl J Med; 2015 Jun; 372(26):2481-98. PubMed ID: 26061751
[TBL] [Abstract][Full Text] [Related]
14. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
[TBL] [Abstract][Full Text] [Related]
15. The Misclassification of Diffuse Gliomas: Rates and Outcomes.
Iorgulescu JB; Torre M; Harary M; Smith TR; Aizer AA; Reardon DA; Barnholtz-Sloan JS; Perry A
Clin Cancer Res; 2019 Apr; 25(8):2656-2663. PubMed ID: 30635340
[TBL] [Abstract][Full Text] [Related]
16. Easy-to-use machine learning system for the prediction of IDH mutation and 1p/19q codeletion using MRI images of adult-type diffuse gliomas.
Nishikawa T; Ohka F; Aoki K; Suzuki H; Motomura K; Yamaguchi J; Maeda S; Kibe Y; Shimizu H; Natsume A; Innan H; Saito R
Brain Tumor Pathol; 2023 Apr; 40(2):85-92. PubMed ID: 36991274
[TBL] [Abstract][Full Text] [Related]
17. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.
Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY
J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems.
Sonoda Y
Int J Clin Oncol; 2020 Jun; 25(6):1004-1009. PubMed ID: 32020379
[TBL] [Abstract][Full Text] [Related]
19. A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.
Santosh V; Rao S
Indian J Pathol Microbiol; 2022 May; 65(Supplement):S14-S23. PubMed ID: 35562130
[TBL] [Abstract][Full Text] [Related]
20. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
